甲基多巴和拉贝洛尔治疗妊娠期高血压疾病的系统评价

发布时间：2019-03-13 21:12

【摘要】：目的系统评价甲基多巴和拉贝洛尔治疗妊娠期高血压疾病的有效性及安全性。方法检索Med Line,Cochrane Library,EMbase,中国知网、万方、维普等数据库中公开发表的甲基多巴和拉贝洛尔治疗妊娠期高血压疾病的随机对照研究,试验组予以甲基多巴治疗,对照组予以拉贝洛尔治疗。用Rev Man 5.3软件进行Meta分析。结果共纳入10项随机对照研究,共计1285例患者。试验组和对照组的重度高血压发生率分别为6.62%和12.21%,蛋白尿发生率分别为15.57%和8.52%,药物不良反应发生率分别为21.82%和25.63%,胎儿/婴儿死亡率分别为4.19%和2.84%,差异均无统计学意义(均P0.05)。试验组的浆黏度明显低于对照组,差异有统计学意义(RR=0.77,95%CI=0.64~0.90,P0.001)。结论甲基多巴和拉贝洛尔治疗妊娠期高血压疾病降压疗效和安全性相当,但甲基多巴在改善血浆黏度上明显优于拉贝洛尔。
[Abstract]:Objective to evaluate the efficacy and safety of methyldopa and Rabelolol in the treatment of hypertensive disorder complicating pregnancy. Methods A randomized controlled study of methyldopa and labelolol published in the databases of Med Line,Cochrane Library,EMbase, Wanfang, Vip and other databases was conducted in the treatment of hypertensive disorder complicating pregnancy (hypertensive disorder complicating pregnancy), and the trial group was treated with methyldopa. The control group was treated with Labelolol. Meta analysis was carried out with Rev Man 5.3 software. Results A total of 1285 patients were enrolled in 10 randomized controlled studies. The incidence of severe hypertension, proteinuria and adverse drug reactions were 6.62% and 12.21%, 15.57% and 8.52%, 21.82% and 25.63%, respectively. The fetal / infant mortality rates were 4.19% and 2.84%, respectively, and there was no significant difference (P0.05). The viscosity of the test group was significantly lower than that of the control group, the difference was statistically significant (RR=0.77,95%CI=0.64~0.90,P0.001). Conclusion the efficacy and safety of methyldopa and Labelolol in the treatment of hypertensive disorder complicating pregnancy are similar, but methyldopa is superior to Labelolol in improving plasma viscosity.
【作者单位】：北京大学人民医院药剂科;
【基金】：国家自然科学基金资助项目(81503050)
【分类号】：R714.246

【相似文献】